Institution Directory

Clinical trials at Beth Israel Deaconess Medical Center

Sites in Boston, MA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 3:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

622

Shown on this page

Current sort

Live official records

Conditions: Metastatic Breast Cancer, Invasive Breast Cancer, Somatic Mutation Breast Cancer (BRCA1), Somatic Mutation Breast Cancer (BRCA2), CHEK2 Gene Mutation, ATM Gene Mutation, PALB2 Gene Mutation, RAD51 Gene Mutation, BRIP1 Gene Mutation, NBN Gene Mutation
Interventions: Olaparib; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 20
States / cities: Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 15 more

Conditions: Stroke, Thromboses, Intracranial, Aneurysm, Brain
Interventions: Stroke/Thrombectomy/Aneurysm-specific surgical procedures; Procedure
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 1 Year to 120 Years
Enrollment: 40,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2055
U.S. locations: 54
States / cities: Birmingham, Alabama • Loma Linda, California • Santa Barbara, California + 48 more

Conditions: Atopic Dermatitis
Interventions: Placebo, Upadacitinib, Topical corticosteroids (TCS); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 1,533 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 59
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more

Conditions: Breast Cancer
Interventions: Ribociclib, Endocrine therapy; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 3
States / cities: Boston, Massachusetts • Danvers, Massachusetts

Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Interventions: Clinical Observation, Crizotinib, Laboratory Biomarker Analysis; Other · Drug
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2036
U.S. locations: 1613
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 978 more

Conditions: Preterm Pregnancy, Premature Birth
Interventions: Educational intervention; Behavioral
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 18 Years to 99 Years
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 3
States / cities: Boston, Massachusetts • Weymouth, Massachusetts

Conditions: Hypoxic Ischemic Brain Injury, Neonatal Encephalopathy
Interventions: Near-Infrared Spectroscopy (NIRS); Device
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Up to 2 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation, Complete Response, Partial Response, First Line Platinum Chemotherapy
Interventions: Olaparib 300mg tablets; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2028
U.S. locations: 81
States / cities: Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 63 more

Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Interventions: Venetoclax, Zanubrutinib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 4
States / cities: Scarborough, Maine • Boston, Massachusetts • South Weymouth, Massachusetts

Conditions: Advanced Solid Tumor
Interventions: OMTX705, Pembrolizumab, Tislelizumab (BGB-A317); Drug
Lead sponsor: Oncomatryx Biopharma S.L.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atrial Arrhythmia, Atrium; Fibrillation, Atrial Tachycardia
Interventions: electrophysiology study and ablation with an Abbott Ablation Catheter; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: Not listed
Enrollment: 200 participants
Timeline: 2022 – 2026
U.S. locations: 20
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Rancho Mirage, California + 16 more

Conditions: Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer
Interventions: Paclitaxel, Pertuzumab, Margetuximab, Trastuzumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 14
States / cities: Washington D.C., District of Columbia • Boston, Massachusetts • Foxborough, Massachusetts + 8 more

About this Beth Israel Deaconess Medical Center institution page

What this page lists: ClinicalTrials.gov records that list Beth Israel Deaconess Medical Center in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Beth Israel Deaconess Medical Center

Filter and sort this campus

Live official records

Olaparib In Metastatic Breast Cancer

Stroke Thrombectomy and Aneurysm Registry

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Optimizing Family Counseling for Anticipated Extremely Preterm Delivery

Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.

Abbott Atrial Fibrillation Post Approval Study

MARGetuximab Or Trastuzumab (MARGOT)

About this Beth Israel Deaconess Medical Center institution page